Ubiquitin-mediated signalling and Paget's disease of bone

被引:12
作者
Layfield, Robert [1 ]
Shaw, Barry [1 ]
机构
[1] Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England
关键词
D O I
10.1186/1471-2091-8-S1-S5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Multiple steps in the RANK-NF-kappa B signalling pathway are regulated by ubiquitylation. Mutations affecting different components of this pathway, including the ubiquitin binding p62 signalling adapter protein, are found in patients with Paget's disease of bone or related syndromes. Here, we review the molecular defects and potential disease mechanisms in these conditions and conclude that the mutations may confer a common increased sensitivity of osteoclasts to cytokines, resulting in disordered NF-kappa B-dependent osteoclast function. Modulation of the osteoclast RANK-NF-kappa B signalling axis may represent a viable therapeutic strategy for Paget's disease and other conditions where excessive bone resorption or remodelling is a feature.
引用
收藏
页数:7
相关论文
共 44 条
[1]
[Anonymous], 1992, PATHOPHYSIOLOGY TREA
[2]
VCP (p97) regulates NFκB signaling pathway, which IS important for metastasis of osteosarcoma cell line [J].
Asai, T ;
Tomita, Y ;
Nakatsuka, S ;
Hoshida, Y ;
Myoui, A ;
Yoshikawa, H ;
Aozasa, K .
JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (03) :296-304
[3]
Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone [J].
Cavey, J. R. ;
Ralston, S. H. ;
Sheppard, P. W. ;
Ciani, B. ;
Gallagher, T. R. A. ;
Long, J. E. ;
Searle, M. S. ;
Layfield, R. .
CALCIFIED TISSUE INTERNATIONAL, 2006, 78 (05) :271-277
[4]
Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations [J].
Cavey, JR ;
Ralston, SH ;
Hocking, LJ ;
Sheppard, PW ;
Ciani, B ;
Searle, MS ;
Layfield, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (04) :619-624
[5]
Recent advances in understanding the mechanism of action of bisphosphonates [J].
Coxon, Fraser P. ;
Thompson, Keith ;
Rogers, Michael J. .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (03) :307-312
[6]
Crockett JC, 2006, J BONE MINER RES, V21, P1154
[7]
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype [J].
Cundy, T ;
Hegde, M ;
Naot, D ;
Chong, B ;
King, A ;
Wallace, R ;
Love, DR ;
Seidel, J ;
Fawkner, M ;
Banovic, T ;
Callon, KE ;
Grey, AB ;
Reid, IR ;
Middleton-Hardie, CA ;
Cornish, J .
HUMAN MOLECULAR GENETICS, 2002, 11 (18) :2119-2127
[8]
Brief report: Recombinant osteoprotegerin for juvenile Paget's disease [J].
Cundy, T ;
Davidson, J ;
Rutland, MD ;
Stewart, C ;
DePaoli, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (09) :918-923
[9]
Involvement of valosin-containing protein, an ATPase co-purified with IκBα and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IκBα [J].
Dai, RM ;
Chen, EY ;
Longo, DL ;
Gorbea, CM ;
Li, CCH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) :3562-3573
[10]
Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase -: Identification of a novel TRAF6 interaction motif [J].
Darnay, BG ;
Ni, J ;
Moore, PA ;
Aggarwal, BB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) :7724-7731